Zosano's efficient drug delivery platform generates more commercial opportunities than we can pursue independently. Strategic partnering is therefore a critical component of our ability to advance Zosano's novel therapeutics programs into clinical development and onto the market.
Zosano’s objective is to selectively partner at strategic stages of the development process while retaining select therapeutic programs to develop independently. We want to strategically integrate our proprietary transdermal technology platform into the best possible companies to insure we achieve the most rapid development of therapeutics which utilize our base technology. This strategy will enable the Company to maximize the number of lead compounds it can rapidly put into development as it continues to harvest output and develop its platform to a higher degree of productivity. Zosano pursues the following types of collaborations:
Licensing and/or co-development arrangements for our clinical pipeline products and pre-clinical drugs in development. Zosano can collaborate to develop therapeutics from our existing programs of both proteins/peptides and small molecules. Partners may choose to advance these programs independently or in conjunction with Zosano.
Partners may also work with Zosano to augment their own pipelines by utilizing our propriety transdermal delivery technology in conjunction with the partner’s products. Thereby insuring long term life cycle management for critical internal programs
Our goal is to be the partner of choice in providing the most rapid, efficient and cost effective pathway for developing high quality transdermal delivered therapeutics to treat serious health conditions. Zosano brings a full range of capabilities to the drug delivery development and manufacturing process, making the company the ideal partner for many of the industry’s leading pharmaceutical and biotechnology companies.
For further information regarding business development interests with Zosano Pharma, please contact: